Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S3.79
P/E—
Fwd P/E16.81
PEG1.93
52W— – —
RSI—
Target$120.21 (+17.9%)
Beta0.59
Div2.40%
Loading chart…
RSI ()
Loading patterns…
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 33
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
7Bullish
2Bearish
0Neutral
Key Signals 2
▲ Double Bottom
Major reversal
2026-06-25 · $92.07
Two lows ~$85.41 — bullish reversal confirmed
Learn more →
▲ Double Bottom
Major reversal
2026-07-16 · $97.44
Two lows ~$87.05 — bullish reversal confirmed
Learn more →
Momentum Signals 7
▲ MACD Bullish Crossover
▲ Bull Flag
▲ MACD Bullish Crossover
▲ Bull Flag
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$120.21
+17.9% upside
Low $103
—
High $135
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
56.85%Last 12 Months
Operating Margin
14.71%Last 12 Months
Return on Equity
10.58%Last 12 Months
Revenue Growth
13.00%Year over Year
Free Cash Flow
7.21BLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
63.21Most Recent Quarter
Current Ratio
1.38Most Recent Quarter
Cash
5.60BMost Recent Quarter
Total Debt
32.72BMost Recent Quarter
Net Debt
—Most Recent Quarter
How ABT Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 176.41B |
| Enterprise Value | 204.18B |
| Trailing P/E | 33.43 |
| Forward P/E | 16.81 |
| PEG Ratio (5yr) | 1.93 |
| Price/Sales (ttm) | 3.79 |
| Price/Book (mrq) | 3.45 |
| EV/Revenue | 4.38 |
| EV/EBITDA | 17.48 |
Share Statistics
| Avg Vol (3m) | 10.95M |
| Shares Outstanding | 1.73B |
| Float | 1.72B |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 81.82% |
| Short Ratio | 2.83 |
| Short % of Float | 1.43% |
Profitability
| Gross Margin | 56.85% |
| Operating Margin (ttm) | 14.71% |
| Profit Margin | 11.65% |
| Return on Assets (ttm) | 5.33% |
| Return on Equity (ttm) | 10.58% |
Income Statement
| Revenue (ttm) | 46.58B |
| Revenue Growth (yoy) | 13.00% |
| Gross Profit (ttm) | 26.48B |
| EBITDA | 11.68B |
| Net Income (ttm) | 5.40B |
| Diluted EPS (ttm) | 3.05 |
| EPS Growth (yoy) | -47.50% |
Balance Sheet
| Total Cash (mrq) | 5.60B |
| Total Debt (mrq) | 32.72B |
| Debt / Equity (mrq) | 63.21 |
| Current Ratio (mrq) | 1.38 |
| Book Value / Share | 29.54 |
| Operating CF (ttm) | 9.91B |
| Free Cash Flow (ttm) | 7.21B |
Trading & Dividends
| Beta (5Y) | 0.59 |
| 50-Day MA | 105.10 |
| 200-Day MA | 105.98 |
| Fwd Dividend Yield | 2.44% |
| Payout Ratio | 78.96% |
Income
Dividend Yield
2.40%Last 12 Months
Annual Rate
2.52Forward
Payout Ratio
78.96%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 78.96%
Monthly Dividends
Ownership Breakdown
Institutional 81.82%
Insider 0.50%
Public 17.7%
Short Interest
1.43% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in ABT in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|